BioBusiness

Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.

A thorough understanding of both regulatory requirements and study challenges can help develop and validate the appropriate methods for a bioanalytical study program.

Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.

Roche’s acquisition of Good Therapeutics grants them rights to the company's conditionally activated PD-1-regulated IL-2 program.

SIRIO is enhancing its strategy for small and medium nutrition brands as Lonza’s Sara Lesina joins as GM in Europe.

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.

The Hatch Waxman safe harbor provision exempts otherwise infringing uses of patented materials if they are in furtherance of a regulatory submission, but the use of patented research tools may fall outside its protection.

Pharma loses battle to block price negotiations, but implementation faces many challenges.

While the cost of certain medicines are alarmingly high, they can be considered a bargain measured against a lifetime of traditional costs.

Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.

ChargePoint Technology has acquired single-use container company PuroVaso.

ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.

Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.

Guest contributor B.S. Sathya Durga discusses the importance of modernizing India's pharmaceutical manufacturing industry.

Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is expected to strengthen its sickle cell disease portfolio.

Sartorius’ £415 million (US$429 million) acquisition of Albumedix is intended to bolster its portfolio with recombinant albumin-based solutions.

Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.